Michael Gladstone is a Partner at Atlas Venture, where he builds and invests in innovative therapeutics companies. He earned a BA in biochemical sciences from Harvard College and has been instrumental in the founding and development of numerous biotech firms, including Akero Therapeutics, Day One Biopharmaceuticals, and Third Harmonic Bio.
He is passionate about working alongside world-class entrepreneurs to translate scientific discoveries into new medicines for patients. Michael has a keen interest in cultivating the next generation of biotech leaders and has expressed a strong belief in empowering young talent within the industry.
Before his venture career, Michael conducted HIV vaccine research at Beth Israel Deaconess Medical Center.
Michael Gladstone
Partner at Atlas Venture
Greater Boston, United States
Overview
Topics They Care About
Biotech Company Creation
His primary professional focus is building and investing in early-stage innovative therapeutics companies from the ground up.
Venture Investing
As a Partner at Atlas Venture, he is a key decision-maker for the firm's funds, which focus on seed and Series A investments in life sciences.
Therapeutic Innovation
He frequently speaks about creating novel medicines and activating biological pathways to address diseases with limited or no treatment options.
Media Appearances
Michael has no verified media appearances
Work History
6-2020
Partner at Atlas Venture
5-2015
Principal at Atlas Venture
3-2012 - 12-2014
Associate at Atlas Venture
12-2009 - 3-2012
Senior Associate Consultant at L.E.K. Consulting
6-2009 - 12-2009
MLSC Fellow at Eutropics Pharmaceuticals
Education
2005 - 2009
BA from Harvard University
More Information
Social Presence :
Prographics :
Exp : 16
Location : Greater Boston, United States
Job Level : Mid-senior
Designation : Partner at Atlas Venture
